Friday, 30 November 2012

Dear Prof Dr Dr Ehlers,

Re: Who's Who Legal: Germany 2013

I would like to congratulate you on being nominated by your peers as one of the leading practitioners in the jurisdiction, and I am delighted to enclose your copy of this publication.

I would be delighted to hear any feedback on this volume, not only in terms of editorial selection and presentation, but also with reference to any of the publications in the Who’s Who Legal series and the development of the series for the future.

Please note that should you require any additional copies of the publication enclosed they are available at the price of £100 per copy (or four copies for £300). If you would like additional copies at this special price then please kindly fill in the field(s) overleaf and fax the completed version back to me on +44 20 7229 6910 at your earliest convenience.

As we are always trying to maximise the effectiveness of our free distribution we would be very grateful for the names of any corporate counsel who feel should receive a complimentary copy of this publication.

I look forward to hearing from you.

Yours sincerely,

Callum Campbell
Managing Editor

Direct: Dial +44 (0)20 7908 1181
E-mail: Callum.Campbell@LBResearch.com
LIFE SCIENCES

Lawyers practising in the life sciences sector in Germany have seen a steady stream of work over the last few years. A focus on developing new products has resulted in a range of demand for legal services, from new innovations to multinational companies. Combined with recent regulatory changes in drug advertising and stricter rules on counterfeit medicines, practitioners are expecting to remain busy. Our research highlights 24 outstanding attorneys, from 19 different firms.

Bird & Bird LLP’s “innovative and dynamic” life sciences sector fields four excellent lawyers. Michael Alt is considered “extremely strong” and “very someone to reckon with”, and his scientific background allows him to apply a market-focused expertise to clients’ queries. Felix Rödiger is “highly regarded” in the automotive and electronics sector, focusing on patent litigation. Ina von Friede is regarded as “one of the best” for her work in drafting and negotiating contracts for clinical and pharmaceutical companies, while the “highly esteemed” Wolfgang von Neurath is “a highly regarded” litigator.

Two lawyers are chosen from Hogan Lovells’ international LLP’s “dedicated and experienced” life sciences practice. Co-head of the firm’s global life sciences industry sector team Lisa Brock acts for leading pharmaceutical and medical device manufacturing companies, and displays “brilliant knowledge” in all product issues. Andreas von Falck focuses on patents litigation, as well as licence acquisition and regulation, for high-profile clients including Merck and Novartis.

From Freshfields Bruckhaus Deringer LLP, two practitioners stand out. “Very sound” Peter Borchardt, whose expertise in cross-jurisdictional technology and pharmaceutical matters makes him particularly popular with US clients. Frank Philipp Hufnagel acts for leading health-care and pharmaceutical companies, and our research identifies him as a “name that stands out”.

Field Fisher Witherwood LLP offers Joachim Felager, who is “highly regarded” for his trial experience spanning more than 24 years. Cord Willhert advises on regulation, compliance and competition for life sciences companies, and has built up client relationships based on his “pragmatic, reliable” approach.

Ulrich Roese from Clifford Chance LLP is a “leading adviser in the pharmaceutical field”, with a practice covering a wide range of contentious and non-contentious life sciences matters. From the same firm, Peter Dierner, “standout practice and buying advice to both foreign and domestic companies to provide innovative solutions to transactional, product development, and regulatory issues. A boutique life sciences firm.

Strater Rechtanwälte has Markus Ambrus, who is “very active” in the areas of health legislation, medical devices, and products, and specialises in both German and European law. From SCW Schwarzenberg, Betjens Schroeder impresses clients with his ability to offer “highly specialised” advice combined with strong commercial awareness. “Respected name” Thilo Repppe from Becker & McKenzie offers regulatory advice to companies at all stages of product development. Christian Dierks, name partner of specialist medical law firm Dierks + Rohde, is a “very strong” practitioner, with a focus on the legal aspects of health insurance, telemedicine and drug regulation.

From Dr. Schmidt-Platten & Romantik, co-founder Wolfgang Kostitschka is “extremely experienced” in advising and representing pharmaceutical entrepreneurs. Thomas Bopp from Glass Lutz is considered “one of the leading names” in the life sciences field, while Peter von Crevitz from Preuß Bolbig & Partner is “very well-known” and “respected” for his work with high-profile pharmaceutical companies.

Alexander Eilers from his own firm stands out for his “profound knowledge” of the life sciences industry. He is nominated in this chapter for his “outstanding, comprehensive advice” to a wide range of clients on pharmaceutical, focusing particularly on manufacturing policy and regulation.

Wolfgang Rahmann, partner in Taylor Wessing’s life sciences practice, is considered “absolutely number one for life sciences regulatory work”, having acted for international businesses in both German and European courts.

From Kühne Biomar backyard, Thomas Reissmann acts on “top of the market deal” and is noted for his “specialised” approach to cross-border patent litigation.

Excluded for his “profound expertise” is Max von Rosspat, name partner of Rosspat Osten Poeppel intellectual Property Rechtsanwälte, whose clients include international biotechnology and pharmaceutical companies. Burkhard Strader from Strater Rechtanwälte is a “very active name in the market”, recognized for his “particular knowledge” of the wider commercial context in which his clients operate.